Cytotoxicity Test of N'-E-benzylidene benzohydrazide in UM-UC-3 and MDA-MB-231 Cell Line

Abstract

The current anticancer therapy strategy that can be done is chemotherapy. Although cisplatin has become a common drug for the clinical treatment of solid tumors, its use has been largely limited due to the inherent and acquired resistance and severe toxic side effects in normal tissues. The search for anticancer drugs continues to this day. Hydrazone compounds are a group of organic compounds derived from reactions between aldehydes or ketones and hydrazine. Hydrazone contains an azomethine bond -CH=N-NH- which has anticancer and antitumor activity. This study aims to determine the cytotoxicity of N'-E-benzylidene benzohydrazide compounds on UM-UC-3 and MDA-MB-231 cancer cell lines. Cytotoxicity analysis was carried out using CCK-8 to obtain the Inhibitory Concentration (IC50) value with a nonlinear regression test using GraphPad Prism 8.3.0 for Windows software. The compound N'-E-benzylidene benzohydrazide was shown to have a lower IC50 value in the MDA-MB-231 cell line at a concentration of 100 µM namely 482 µM. Therefore, the study concludes that N'-E-benzylidene benzohydrazide is still toxic to cancer cell lines, particularly UM-UC-3 and MDA-MB-231 cell lines. More research will be needed before this compound may be used as an anticancer medication in the future.